MX2018002681A - Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1". - Google Patents

Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".

Info

Publication number
MX2018002681A
MX2018002681A MX2018002681A MX2018002681A MX2018002681A MX 2018002681 A MX2018002681 A MX 2018002681A MX 2018002681 A MX2018002681 A MX 2018002681A MX 2018002681 A MX2018002681 A MX 2018002681A MX 2018002681 A MX2018002681 A MX 2018002681A
Authority
MX
Mexico
Prior art keywords
cancer
allergin
antagonist
enhancing immunity
agent
Prior art date
Application number
MX2018002681A
Other languages
English (en)
Inventor
Shibayama Shiro
Arima Hiroshi
SIMBO Takuya
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2018002681A publication Critical patent/MX2018002681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un objeto de la presente invención es proporcionar un agente para la supresión del progreso de, la supresión de la recurrencia de y/o el tratamiento del cáncer, que contiene un nuevo ingrediente activo capaz de mejorar la inmunidad contra el cáncer. El antagonista de ``Allergin-1´´ de acuerdo con la presente invención es capaz de mejorar la inmunidad contra el cáncer y puede usarse para la supresión del progreso de, la supresión de la recurrencia de y/o el tratamiento del cáncer. Particularmente, el antagonista de ``Allergin-1´´ según la presente invención es útil en una terapia de un paciente con cáncer con una eficacia terapéutica insuficiente por un agente inmunoterapéutico tumoral, o una terapia contra el cáncer en combinación con un fármaco anticáncer.
MX2018002681A 2015-09-03 2016-09-02 Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1". MX2018002681A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015173659 2015-09-03
JP2016138374 2016-07-13
PCT/JP2016/075887 WO2017038997A1 (ja) 2015-09-03 2016-09-02 Ａｌｌｅｒｇｉｎ－１アンタゴニストによるがん免疫増強剤

Publications (1)

Publication Number Publication Date
MX2018002681A true MX2018002681A (es) 2018-04-13

Family

ID=58189017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002681A MX2018002681A (es) 2015-09-03 2016-09-02 Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".

Country Status (22)

Country Link
US (2) US11638744B2 (es)
EP (1) EP3345618B1 (es)
JP (2) JP6156604B1 (es)
KR (1) KR102611244B1 (es)
CN (1) CN108025069B (es)
AU (1) AU2016317378B2 (es)
CA (1) CA2997240C (es)
DK (1) DK3345618T3 (es)
ES (1) ES2905554T3 (es)
HU (1) HUE058293T2 (es)
IL (1) IL257773B (es)
MX (1) MX2018002681A (es)
MY (1) MY197664A (es)
NZ (1) NZ740351A (es)
PH (1) PH12018500450A1 (es)
PL (1) PL3345618T3 (es)
PT (1) PT3345618T (es)
RU (1) RU2734777C2 (es)
SG (1) SG11201801699VA (es)
TW (1) TWI765862B (es)
WO (1) WO2017038997A1 (es)
ZA (1) ZA201801471B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2970873C (en) * 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2023123337A1 (en) * 2021-12-31 2023-07-06 Dalian University Of Technology Leukemia-related marker and use thereof
WO2024043227A1 (ja) * 2022-08-23 2024-02-29 小野薬品工業株式会社 二重特異性抗体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0846762A3 (en) * 1992-11-17 1998-09-23 Icos Corporation Novel V31 seven transmembrane receptors
US20030232411A1 (en) 1997-12-26 2003-12-18 Ono Pharmaceutical Co., Ltd. Novel polypeptide, cDNA encoding the same, and use thereof
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US6872548B2 (en) * 2001-01-31 2005-03-29 Human Genome Sciences, Inc. Scaffolded fusion polypeptides and compositions and methods for making the same
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
KR20060013426A (ko) * 2003-05-30 2006-02-09 니뽄 신야쿠 가부시키가이샤 Ｂｃｌ-2의 발현을 억제하는 올리고 이중쇄 ＲＮＡ와그것을 함유하는 의약 조성물
EP3115057B1 (en) 2004-10-21 2019-09-04 ONO Pharmaceutical Co., Ltd. Use of immunesuppressant receptor
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP2007538A4 (en) * 2006-03-31 2011-04-20 Centocor Ortho Biotech Inc BINDING PARTNER WITH MODIFIED IMMUNOGLOBULINDOMAS FOR EXTENDED SEMI-VALUE TIME
WO2007122815A1 (ja) 2006-04-14 2007-11-01 Ono Pharmaceutical Co., Ltd. Ｂｉｒ１に対する二価抗体
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
MX2010002018A (es) * 2007-08-20 2010-05-27 Oncotherapy Science Inc Peptido de cdh3 y agente medicinal que comprende al mismo.
EP2331130B1 (en) * 2008-04-09 2018-02-14 Oncoquest Inc. Ige antibodies for the treatment of cancer
KR101258456B1 (ko) * 2011-01-13 2013-04-26 강원대학교산학협력단 백혈구의 혈관외유출 억제 활성 및 비만세포 탈과립 억제 활성을 갖는 펩타이드를 포함하는 약학 조성물
US9381210B2 (en) * 2013-04-15 2016-07-05 Wisconsin Alumni Research Foundation Induced pluripotent stem cell model of chronic myeloid leukemia revealed olfactomedin 4 as a novel therapeutic target in leukemia stem cells
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN108136001B (zh) * 2015-04-03 2022-07-29 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症

Also Published As

Publication number Publication date
RU2018107687A (ru) 2019-10-03
AU2016317378A1 (en) 2018-03-29
HUE058293T2 (hu) 2022-07-28
SG11201801699VA (en) 2018-04-27
EP3345618A1 (en) 2018-07-11
IL257773A (en) 2018-04-30
PT3345618T (pt) 2022-02-02
CA2997240A1 (en) 2017-03-09
MY197664A (en) 2023-06-30
EP3345618B1 (en) 2022-01-05
WO2017038997A1 (ja) 2017-03-09
CA2997240C (en) 2024-04-02
EP3345618A4 (en) 2019-03-13
ES2905554T3 (es) 2022-04-11
US20230256054A1 (en) 2023-08-17
NZ740351A (en) 2022-10-28
AU2016317378B2 (en) 2021-11-11
JP6750559B2 (ja) 2020-09-02
CN108025069A (zh) 2018-05-11
PH12018500450A1 (en) 2018-09-10
CN108025069B (zh) 2021-11-12
KR102611244B1 (ko) 2023-12-06
JP2018016619A (ja) 2018-02-01
ZA201801471B (en) 2019-06-26
JP6156604B1 (ja) 2017-07-05
IL257773B (en) 2021-08-31
KR20180041687A (ko) 2018-04-24
DK3345618T3 (da) 2022-02-07
RU2734777C2 (ru) 2020-10-23
TWI765862B (zh) 2022-06-01
PL3345618T3 (pl) 2022-03-28
US20180244771A1 (en) 2018-08-30
RU2018107687A3 (es) 2020-02-21
TW201712035A (zh) 2017-04-01
US11638744B2 (en) 2023-05-02
JPWO2017038997A1 (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
MY187540A (en) Compounds active towards bromodomains
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
MX2017009608A (es) Compuestos anticancerigenos.
MX2017004723A (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
NZ752037A (en) Medicinal use of serrulatane diterpenes
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
NZ725067A (en) Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer